Evidence of Dose Variability and Dosing Below the FDA and EMA Recommendations for Intravenous Colistin (Polymyxin E) Use in Children and Neonates

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Intravenous colistin (polymyxin E) has renewed interest as a last-line treatment against antimicrobial-resistant gram-negative bacterial infections, despite limited literature on pediatric prescribing practices. Point-prevalence surveys were used to obtain intravenous colistin prescribing data from 78 children and neonates, showing high variability, and 60.3% received doses below the Food and Drug Administration and the European Medicines Agency recommendations.
Original languageEnglish
JournalThe Pediatric Infectious Disease Journal
Early online date22 Jun 2020
Publication statusEarly online date - 22 Jun 2020

Fingerprint

Dive into the research topics of 'Evidence of Dose Variability and Dosing Below the FDA and EMA Recommendations for Intravenous Colistin (Polymyxin E) Use in Children and Neonates'. Together they form a unique fingerprint.

Cite this